Medicure Inc (TSXV:MPH)(OTC:MCUJF), a pharmaceutical company focused on the development and commercialisation of therapies for the US cardiovascular market, yesterday announced its financial results for the quarter ended 30 September 2019.

Net revenues for the three months ended 30 September 2019 were USD5.5m compared to USD7.4m for the three months ended 30 September 2018. The company reported net revenue from the sale of AGGRASTAT (tirofiban hydrochloride) of USD5.3m in the quarter ended 30 September 2019 compared to USD7m for the quarter ended 30 September 2018.

The firm posted adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) for the quarter ended 30 September 2019 at USD319,000 compared to adjusted EBITDA of USD599,000 for the quarter ended 30 September 2018.

Net loss for the quarter ended 30 September 2019 was USD599,000 compared to net loss of USD545,000 for the quarter ended 30 September 2018.